Infectious Disease Update: New Anti-Microbials

Seminars in Cutaneous Medicine and Surgery

Volumn 25, Issue 2, 2006, Pages 94-99

  Yang, Aparche ^a   Kerdel, Francisco A ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Cedars Medical Center Miami   (United States)

Author keywords

anidulafungin; caspofungin; coagulase negative staphylococci; daptomycin; fungal infections; methacillin resistant Staphylococcus aureus; micafungin; skin and skin structure infections; tigecycline; vancomycin resistant Staphylococcus aureus

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; AZTREONAM; CASPOFUNGIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ECHINOCANDIN; ERTAPENEM; FLUCONAZOLE; FLUCYTOSINE; LINEZOLID; MACROLIDE; METICILLIN; MICAFUNGIN; OXACILLIN; PENICILLIN G; POLYENE ANTIBIOTIC AGENT; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TIGECYCLINE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE;

ABDOMINAL INFECTION; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ASPERGILLOSIS; BACTERIAL INFECTION; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ESOPHAGUS CANDIDIASIS; GRAM POSITIVE BACTERIUM; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOKALEMIA; INFECTION CONTROL; LEUKOPENIA; LIVER FUNCTION TEST; MYCOSIS; MYOPATHY; NAUSEA; NEPHROTOXICITY; NONHUMAN; OROPHARYNX CANDIDIASIS; PARASITE; PHLEBITIS; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; SKIN STRUCTURE; UNITED STATES; VOMITING;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; DERMATOMYCOSES; HUMANS; SKIN DISEASES, BACTERIAL;

EID: 33746868888     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2006.04.006     Document Type: Review

References (59)

1. U.S. Food and Drug Administration. Guidance for industry. Uncomplicated and complicated skin structure infections-developing antimicrobial drugs for treatment (2006). http://www.fda.gov/cder/guidance/2566dft.pdf Availablet at. http://www.fda.gov/cder/guidance/2566dft.pdf. Accessed May 4.
2. Krcmery Jr. V., Kunova E., Jesenska Z., et al. Invasive mold infections in cancer patients. 5 years' experience with Aspergillus, Mucor, Fusarium and Acremonium infections. Support Care Cancer 4 (1996) 39-45
3. Levy S.B. The Antibiotic Paradox (1992), Plenum Press, New York
4. BarberM. Methicillin-resistant staphylococci. J Clin Pathol 14 (1961) 385-393
5. Diekema DJ, Pfaller MA, Schmitz FJ, et al; SENTRY Participants Group: Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.
6. Critchley I.A., Draghi D.C., Sahm D.F., et al. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 51 (2003) 639-649
7. Appelbaum P.C., and Jacobs M.R. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr Opin Microbiol 8 (2005) 510-517
8. Fritsche T.R., and Jones R.N. Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int J Antimicrob Agents 24 (2004) 567-571
9. Betriu C., Casado M.C., Gomez M., et al. Incidence of erythromycin resistance in Streptococcus pyogenes. a 10-year study. Diagn Microbiol Infect Dis 33 (1999) 255-260
10. Appelbaum P.C., and Bozdogan B. Vancomycin resistance in Staphylococcus aureus. Clin Lab Med 24 (2004) 381-402
11. Cui L., Tominaga E., Neoh H.M., et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50 (2006) 1079-1082
12. Tally F.P., and DeBruin M.F. Development of daptomycin for Gram-positive infections. J Antimicrobial Chemother 46 (2000) 523-526
13. Silverman J.A., Perlmutter N.G., and Shapiro H.M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus antimicrob. Agents Chemother 47 (2003) 2538-2544
14. Woodworth J.R., Nyhart Jr. E.H., Brier G.L., et al. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 36 (1992) 318-325
15. Dvorchik B., Arbeit R.D., Chung J., et al. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 48 (2004) 2799-2807
16. Cha R., Grucz Jr. R.G., and Rybak M.J. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 47 (2003) 1598
17. Sader H.S., Fritsche T.R., Streit J.M., et al. Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003. J Chemother 17 (2005) 477-483
18. Sader H.S., Fritsche T.R., and Jones R.N. Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003). Diagn Microbiol Infect Dis 53 (2005) 329-332
19. Johnson A.P., Mushtaq S., Warner M., et al. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Int J Antimicrob Agents 24 (2004) 315-319
20. Arbeit R.D., Maki D., Tally F.P., et al., Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38 (2004) 1673-1681
21. Van der Auwera P. Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin. Antimicrob Agents Chemother 33 (1989) 1783-1790
22. Woodworth J.R., Nyhart Jr. E.H., Brier G.L., et al. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 36 (1992) 318-325
23. Dvorchik B., Arbeit R.D., Chung J., et al. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 48 (2004) 2799-2807
24. Dvorchik B.H., Brazier D., DeBruin M.F., et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 47 (2003) 1318-1323
25. Zhanel G.G., Homenuik K., Nichol K., et al. The glycylcyclines. a comparative review with the tetracyclines. Drugs 64 (2004) 63-88
26. Bouchillon S.K., Hoban D.J., Johnson B.M., et al. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates. 2001 to 2002. Diagn Microbiol Infect Dis 51 (2005) 291-295
27. Livermore D.M. Tigecycline. what is it, and where should it be used?. J Antimicrob Chemother 56 (2005) 611-614
28. Muralidharan G., Micalizzi M., Speth J., et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 49 (2005) 220-229
29. Zhanel G.G., Homenuik K., Nichol K., et al. The glycylcyclines. a comparative review with the tetracyclines. Drugs 64 (2004) 63-88
30. Bouchillon S.K., Hoban D.J., Johnson B.M., et al. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates. 2001 to 2002. Diagn Microbiol Infect Dis 51 (2005) 291-295
31. Breedt J., Teras J., Gardovskis J., et al., Tigecycline 305 cSSSI Study Group. Safety and efficacy of tigecycline in treatment of skin and skin structure infections. results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 49 (2005) 4658-4666
32. Fritsche T.R., and Jones R.N. Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int J Antimicrob Agents 24 (2004) 567-571
33. Muralidharan G., Micalizzi M., Speth J., et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 49 (2005) 220-229
34. Bouchillon S.K., Hoban D.J., Johnson B.M., et al. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates. 2001 to 2002. Diagn Microbiol Infect Dis 51 (2005) 291-295
35. Jacobus N.V., McDermott L.A., Ruthazer R., et al. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother 48 (2004) 1034-1036
36. Sacchidanand S., Penn R.L., Embil J.M., et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections. results from a phase 3, randomized, double-blind trial. Int J Infect Dis 9 (2005) 251-261
37. Breedt J., Teras J., Gardovskis J., et al., Tigecycline 305 cSSSI Study Group. Safety and efficacy of tigecycline in treatment of skin and skin structure infections. results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 49 (2006) 4658-4666
38. UpToDate Online. http://utdol.com; search term: tigecycline
39. Denning D.W. Echinocandin antifungal drugs. Lancet 362 (2003) 1142-1151
40. Espinel-Ingroff A., Barchiesi F., Cuenca-Estrella M., et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 43 (2005) 3884-3889
41. Sanglard D., and Odds F.C. Resistance of Candida species to antifungal agents. molecular mechanisms and clinical consequences. Lancet Infect Dis 2 (2002) 73-85
42. Ostrosky-Zeichner L., Kontoyiannis D., Raffalli J., et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 24 (2005) 654-661
43. Moore C.B., Sayers N., Mosquera J., et al. Antifungal drug resistance in Aspergillus. J Infect 41 (2000) 203-220
44. Hebert M.F., Blough D.K., Townsend R.W., et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45 (2005) 1018-1024
45. https://utdol.com; search term: caspofungin
46. Denning D.W. Echinocandin antifungal drugs. Lancet 362 (2003) 1142-1151
47. Park S., Kelly R., Kahn J.N., et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 49 (2005) 3264-3273
48. Villanueva A., Arathoon E.G., Gotuzzo E., et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33 (2001) 1529-1535
49. Arathoon E.G., Gotuzzo E., Noriega L.M., et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 46 (2002) 451-457
50. Mora-Duarte J., Betts R., Rotstein C., et al., Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
51. Colombo A.L., Perfect J., DiNubile M., et al. Global distribution and outcomes for Candida species causing invasive candidiasis. results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22 (2003) 470-474
52. Walsh T.J., Teppler H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 (2004) 1391-1402
53. https://utdol.com; search term: micafungin
54. de Wet N., Llanos-Cuentas A., Suleiman J., et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 39 (2004) 842-849
55. van Burik J.A., Ratanatharathorn V., Stepan D.E., et al., National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39 (2004) 1407-1416
56. Hebert M.F., Smith H.E., Marbury T.C., et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 45 (2005) 1145-1152
57. ERAXIS for injection (2006). http://www.pfizer.com/pfizer/download/uspi_eraxis.pdf Available at. http://www.pfizer.com/pfizer/download/uspi_eraxis.pdf. Accessed May 4.
58. Krause D.S., Simjee A.E., van Rensburg C., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 39 (2004) 770-775
59. Pfaller M.A., Diekema D.J., Boyken L., et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agents Chemother 49 (2005) 4795-4797